Featured Articles

  1. The Case For Reciprocal Due Diligence In Life Sciences Board Recruitment 10/1/2026

    Candidates for seats on company boards should scrutinize governance, culture, and leadership dynamics before saying yes, writes DeeDee DeMan.

  2. Targeting p27 To 'Let Biology Do The Work' With Stacy Blain, CEO, Concarlo Therapeutics 9/29/2026

    Stacy Blain, PhD, turned 30 years of p27 research into Concarlo’s LOCKTAC, a molecular glue designed to restore natural CDK2/4/6 inhibition in cancer.

  3. The Strength Behind Servant Leadership 9/28/2026

    Servant leadership means putting people first because results follow people, not the other way around, writes Boehringer Ingelheim’s Christine Sakdalan.

  4. How To Choose A Contract Sales Organization For A 2027 Launch 9/22/2026

    Five of the best-known contract sales providers have changed owners, leaders, or reporting structure since 2022. Contracts should reflect those changes, writes Hoyt Gong.

  5. Wall Street Is Wary Of NAMs — And For Good Reason: What Happens To Yesterday's Drugs? 9/15/2026

    Part 2 follows the consequences into Wall Street, asking what better evidence could mean for pharmaceutical valuations and, ultimately, drugs already in the portfolio.

  6. What Strong Biotech IP Strategies Get Right And Where Weak Ones Break Down 9/11/2026

    Without the right patent strategy, drug developers risk losing investors and sacrificing commercial potential.

  7. When Should R&D Organize Around The Therapy, Not Just The Drug? 9/9/2026

    Deciding whether a drug candidate should be developed as part of a combination or not should hinge on available evidence and a company’s therapeutic hypothesis. 

  8. Your Trial Shows Up In AI. Now What? 9/3/2026

    AI can explain your trial — but can it help patients act? Ross Jackson shares how sponsors can turn visibility into trust and next steps.

  9. Four Implications Of The Phase 3 Cancer Vaccine Results 9/1/2026

    Merck and Moderna's Phase 3 results in melanoma offer the strongest validation yet for personalized cancer vaccines, writes Devan Shah.

  10. When Should R&D Turn Back? 8/28/2026

    Good R&D leadership is knowing when to keep investing in a development program, when to change course, and when to return to base, writes David Adler, M.D./Ph.D., MBA.